Search - tctmd.com

Displaying 321 - 340 of 2029

Sort: Relevancy | Date

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

News Conference News TCT 2015

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

October 13, 2015

News Conference News TCT 2015

Debaters Question Need for Further Stent Innovation

Todd Neale

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Industry News

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

October 12, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Industry News

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

October 12, 2015

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Industry News

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

Advertisement

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

IN.PACT SFA: Benefits of DCB Persist at 2 Years

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

Debaters Question Need for Further Stent Innovation

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content